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Abstract
After 33 years of the identification of HIV-1 infection, very little is known about the role
of host cellular proteins. Till now considerable work has been done in the area of host-
pathogen interactions facilitated by the viral proteins and host receptors. The role of the
main receptor CD4 and co-receptors like CCR5, CXCR4 and their alternative receptors
were well studied in disease progression. But the intracellular events during the host-
pathogen interactions were poorly understood. Much data is available based on the glob‐
al analysis of genome-wide RNA interference screens, yeast two-hybrid system and co-
immunoprecipitation studies but their exact roles are not yet characterized. There are
very few host proteins like APOBEC3G, LEDGF/p75, INI1, HMG I(Y), BAF which are
well studied and characterized. Majority of the reported proteins are attributed to multi‐
ple functions. It will be useful to study such proteins to develop as future candidates in
HIV-1 therapeutics.
Keywords: HIV, Reverse transcription, Host proteins, CD4, CCR5, CXCR4, Topoisomer‐
ase, PICs
1. Introduction
Host cell responses are key determinants of infection pertaining to infectious diseases.
Different kind of host cell responses are exerted during the course of the infection, either a host
defense response to restrict the invasion of pathogen or may promote the invasion. During the
course of evolution, pathogens have acquired capability to protect themselves from host
defense. This protection is mainly by modulating the key regulators of the host signal trans‐
duction mechanism. Unlike other pathogens, viruses are very small with a small genome which
codes for the essential structural proteins and enzymes, a reason to consider them as primitive.
These proteins are enough to takeover host cell and to control majority of the cellular processes.
This takeover property may be due to its dependence on the host mechanisms to fulfill its
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needs to establish itself and for replication in the host. For this they have to suppress certain
mechanisms and promote others. It is very important to know the host factors involved the
host-pathogen interactions, establishment of the infection and pathogenicity. In retrovirus
especially in HIV infection, host proteins requirement starts from the beginning of attachment
of the virus to its target host cell, reverse transcription, integration, transcription and transla‐
tion of viral proteins, carrying of viral proteins to plasma membrane and release of viral
particles. Overall knowledge on host proteins involvement in any infection would increase the
possibilities of invention of the inhibitors for the host proteins which may be candidates for
the future drug inventions.
2. Binding of virus to cell surface
Viruses have remarkable specificity for the host species and the cell types that they can infect.
Similar to other viruses, human immunodeficiency virus (HIV) also has host and exhibits target
cell specificity. This feature is based on the properties of a cell which can fulfill the virus catch
and grab mechanism to complete its infection cycle (from attachment to the production of
progeny viruses is considered as an infection cycle).
HIV as a single particle is called as virion. This virion consists of an outer envelope and inner
capsid. Outer envelope is host derived plasma membrane with host cell surface molecules and
viral transmembrane glycoprotein called gp41, which connects outer surface gp120 glycopro‐
tein expressed from env gene of virus. Capsid is a cone shaped structure made up of a viral
protein p24 (named based on its molecular weight 24 kDa) which is a processed poly-protein
product of virus gene called gag. Envelope glycoprotein is translated as a 160 kDa polyprotein,
later processed into two subunits of 120 kDa and another is 41 kDa by a cellular endo-protease
[1]. One gp120 and one gp41 collectively form a unit and a trimer of this unit enmeshed in the
viral envelope [2, 3]. The gp41 is the transmembrane portion and gp120 is the extracellular
region which works as an anchor to grab the specific host cells. The primary/preliminary target
for this gp120 is CD4 (receptor) and a secondary target is a chemokine receptor (co-receptor)
of host cells.
2.1. Role of CD4
Leucocyte differentiation antigen, CD4 is a cellular receptor for HIV-1, HIV-2 and Simian
immune deficiency virus (SIV). These viruses share CD4 as the common primary receptor and
the binding sites on these viruses are highly conserved [4]. The CD4 receptor is found on CD4
T-cells (high expression) macrophages and dendritic cells (DCs; low expression). A CD4
binding site present on each monomer of gp120. Recruitment of one CD4 molecule on a single
gp120 in the trimeric anchor can induce conformational changes in all three glycoprotein
monomers of the trimer [5]. This binding of gp120 to CD4 can be blocked by the host antibodies
produced against the gp120 of the virus which are called neutralizing antibodies. But due to
variation in gp120 among virus population, there is a lag time in producing enough antibodies
to block virus attachment. Furthermore, the conformational change occurs in the gp120, which
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avoid recognition by the neutralizing antibodies, a process known as conformational masking.
The conformational changes in gp120 allow it to bind to a second receptor on the CD4 cell
surface [6].
The second docking area on the CD4+ cell surface is a chemokine receptor, a seven transmem‐
brane (7TM) co-receptor namely C-C chemokine receptor type 5 (CCR5) or C-X-C chemokine
receptor type 4 (CXCR4). The viral preference of using one co-receptor among others is called
‘viral tropism’. The virus which can infect the macrophages predominantly uses CCR5 as their
co-receptor. About 90% of all HIV infections involve the M-tropic HIV strain. CXCR4, also
called fusin, which is a glycoprotein-linked chemokine receptor used by T-cell infecting (T-
tropic) HIV to attach to the T cell. Indeed some HIV are reported to use co-receptors other than
these two co-receptors like CCR1, CCR2b, CCR3, CCR8, CCR9, CXCR4, CX3CR1/V28,
STRL-33/BONZO/CXCR6, GPR1, GPR15/BOB, APJ, ChemR23, RDC1, and Leukotriene B4
receptor though the mechanisms are unknown.
Once the HIV gp120 has attached to the CD4 molecule, it undergoes conformational changes
which enables the binding of the gp120 to a co-receptor leads to the further structural rear‐
rangements in the gp41 to fuse with the cell membrane and entry of the virions core into the
cell's cytoplasm (Fig. 1). Once within a cell, virus is safe from neutralizing antibodies, but
vulnerable to attack by CD8 cells (cytotoxic T-lymphocytes or CTLs).
Figure 1. Virus and cell surface receptors interactions. In panel (A), schematic diagram represents virion particle and
host cell surface receptors before attachment of the virion to the host. gp120, gp41 and CD4 binding region on gp120 of
virus and CD4 and co-receptors (CCR5/CXCR4) were labeled. In panel (B), the attachment of CD4 in the CD4 binding
site of gp120 and also binding of the co-receptor were shown.
In the absence of CD4, infection is inefficient and its significance in vivo is controversial. More
than this binding and internalization, CD4 is involved in the signal transduction. Binding of
gp120 to the CD4 induces rapid activation of  the ERK/mitogen-activated protein (MAP)
kinase pathway and stimulates expression of cytokine and chemokine genes by the bind‐
ing  of  nuclear  transcription factors  (AP-1,  NF-kB,  and C/EBP)  in  both  T-cell  tropic  and
macrophage tropic strain. The activation of this signaling pathway requires functional CD4
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receptors which is independent of binding to CXCR4 [7,  8].  Signal transduction by CD4
depends on its association with Lck, a src-family tyrosine kinase. Lck, interacts with CD4
with  its  unique  NH2-terminal  domain,  and  interacts  with  other  intracellular  signaling
proteins with its SH2 and SH3 domains. Given the necessity of Lck kinase activity for T
lymphocyte development and for  mature T cell  functions,  perhaps Lck may function at
different stages during T cell activation [9].
2.2. Role of chemokine receptors
Chemokine receptors are seven transmembrane (7TM) domain, G protein–coupled molecules
that mediate the chemotaxis of T cells and phagocytic cells to the areas of inflammation [10].
Chemokine receptors have four domains exposed on the cell surface: the N terminus and three
extracellular loops (E1, E2 and E3). Co-receptors take up different conformations on cell surface
and on different cell types [11, 12], influencing their ability to support HIV infection. For X4
strains, E2 is critical. Deletion of the N terminus of CXCR4 affects some of the strains but not
all [13], although, when present, participates in binding gp120 [14]. The gp120 of HIV-1 is
structurally divided into five regions called Variable regions and represented with V1,V2 etc.
The highly conserved region present between the variable region of gp120 functions as a co-
receptor binding site [15]. In vitro, envelope glycoproteins in soluble form are even capable of
co-receptor mediated signal transduction [16-18] which involves rapid phosphorylation of
GPCRs at the carboxyl-terminal tail [19]. There are 21 potential phosphorylation sites in CXCR4
and only seven in CCR5. Chemokines, small low-molecular weight proteins, are the ligands
that activate and signal through CCR5 and CXCR4 to mediate several cellular functions
including development, leukocyte trafficking, angiogenesis, and immune response [20].
The extracellular loop2 (E2) which is present on the N terminus of the co-receptor, is respon‐
sible for the gp120 binding and HIV entry. After binding of the viral extracellular gp120 to the
host cell surface, a cellular kinase called Focal adhesion kinase interacts with CCR5 [21]. The
affinity of the gp120 and the co-receptors influences the strength of the signal transduction
which can be correlated with the successes of post-fusion events of the virus [22]. This signal
transduction from the co-receptor converts the host non permissive environment to the
permissive environment for the virus establishment in the host. The binding capacity of the
viral gp120 to the host co-receptor has been considered as the viral infectivity. Even though,
the early and late events after co-receptor-gp120 interaction are not completely elucidated, yet
these interactions have an important role in very early events of HIV-1 lifecycle.
2.3. CCR5
Virus using the CCR5 as co-receptor, infects the macrophages called M-tropic virus. This viral
strain has ability to infect other cell types like dendritic cells and CD4 T-cells. Majority of the
viral isolates utilize CCR5 co-receptors for their transmission. M-tropic HIV replicates in
peripheral blood lymphocytes are less virulent and does not form syncytia. Syncytia are
multinuclear cells which are result of cellular fusion.
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The expression of CCR5 was observed on widely diverged cell types [23] and modulated by
pro-inflammatory cytokines. A number of inflammatory CC-chemokines, like MIP-1, RANTES
etc. [24] act as CCR5 agonists while, MCP-3 functions as antagonist. The cytosolic domain of
the CCR5 bound with GPCRs (G-protein coupled receptors) transduces signals upon binding
of ligands to CCR5. The signal transduction include different secondary messengers like
cAMP, Ca2+, PI3-kinase, MAP kinases, as well as other tyrosine kinase cascades [7, 25-31]. The
importance of the CCR5 mediated signaling [32] in HIV-1 infection was observed in CCR5 Δ
32 [33] mutant populations. Homozygous CCR5 Δ 32 hampers HIV's ability to infiltrate
immune cells. Not only this, many other genetic mutations in CCR5 have effect on the
progression and transmission of the HIV-1 infection. This mutation exerts resistance to many
modes of HIV-1 infection [34].
Variation in the levels of chemokines was observed from person to person. In long-term non-
progressors and seronegative individuals (people with repeated exposure to the virus but who
do not become infected), unusually high levels of the CCR5 ligands were observed. These
chemokines could function as natural competitive inhibitors to HIV-1 infection.[35].
2.4. CXCR4
T-tropic HIV uses CXCR4 as a co-receptor which belongs to the family of α-chemokine
receptor. CXCR4 (known as fusin or X4) is also a GPCR with natural ligand CXCL12, known
as Stromal Cell-Derived Factor 1 (SDF-1) [36, 37]. T-tropic virus can induce syncytium (SI) and
are responsible for the rapid disease progression in HIV-positive individuals. During HIV-1
infections X4-tropic virus has the tendency of emergence and maintains higher viral loads and
much lower CD4 cell counts in infected persons. Even though highly virulent, X4 infections
are susceptible to antiretroviral therapy [7]. Mutational effect of CXCR4 in HIV-1 infection is
not known due to its significant role in development and knockout mutant in mice for this
gene is lethal at the embryonic stage [38].
CXCR4 also involved in cell death of CD4+ T-cells which was induced by gp120 indicate an
important in vivo role for CXCR4 mediated signaling. The interaction of gp120 with CXCR4
triggers a cell death pathway of Fas independent, mitochondrial dependent, cytochrome c
mediated activation of caspase-9 and -3 [39]. Membrane fusion dependent CD4+ T-cell death
was observed in the virus strains of X4 and dual tropic (R5X4) [40].
However, majority of in vivo HIV-1 infection is mediated by M-tropic (R5) viruses could able
to lyse their target cells and X4 viruses can kill CXCR4+. It shows that, CD4 has no role in gp120
induced cell death. Moreover, cell lysis and syncytia formation were inhibited in the cells with
high levels of CD4 expression. Interestingly, Glycol protein from non-infectious strains of X4
or R5X4 could not induce cell death [41].
Based on the capability to support infection of CD4+ cell lines, other than CCR5 and CXCR4
more than 14 potential co-receptors were identified in vitro [6] (Table 1). These receptors are
members of (or closely related to) the chemokine receptor family. The significance of other co-
receptors for HIV-1 replication in vivo and pathogenesis remains unclear.
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Recently STRL-33 (CXCR6) functions as co-receptor for HIV-1 infection in primary T-cells [42],
and in thymocytes, CCR8 were identified in vitro [43].
Co-receptors Ligands Role in viral replication
In vitro In vivo
CCR1 MIP-1α, RANTES, MPIF-1, MCP-3 +
CCR2b MCP-1, MCP-2, MCP-3 +
CCR3 Eotaxin, Eotaxin-2, MCP-3, MCP-4, RANTES ++
CCR5 MIP-1α, MIP-1β, RANTES, MCP-2 ++++ ++++
CCR8 I-309 +
CCR9 TECK +
CXCR4 SDF-1 +++ ++
CX3CR1/V28 Fractalkine +
STRL-33/BONZO/CXCR6 CXCL16 +
GPR1 ? +
GPR15/BOB ? +
APJ Apelin +
ChemR23 ? +
RDC1 ? +
Leukotriene B4 receptor Leukotriene B4 +
Table 1. HIV-1 receptors and cell tropism
3. CD4-independent infection
CD4 expression is not uniform in all hematopoietic cells. While, some cell types (T-cells)
express high levels of CD4, others, including macrophages and dendritic cells (DCs), express
barely detectable amounts. But T-cells as well as macrophages are susceptible to the HIV-1
infection in vivo. This susceptibility reveals the existence of alternative host cell surface
receptors to which, HIV-1 may attach to cells by CD4-independent manner. Sugar groups
present on the both virus and host cell surface (like mannose-specific macrophage endocytosis
receptor) mediate the host pathogen interactions and helps in the HIV-1 infection [44]. Apart
from the sugars, a cell surface protein (DC-SIGN) of dendritic cells [45, 46]. A closely related
receptor to this (DC-SIGNR) on endothelial cells [47], Glycolipids namely galactocerebroside
(GalC), galactosulfatide (sGalC) which express on neurons and glia in the brain, colon
epithelial cell lines and, importantly, on macrophages [48-50] helps in HIV-1 infection. GalC
supports suboptimal entry of particular HIV-1 strains without CD4, although infection
requires a co-receptor [51]. Glycosaminoglycans like heparansulphate involved in the infection
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of HeLa cells [52]. Besides cell surface receptors, cell derived molecules incorporated onto
virions such as integrin ICAM-1 (intercellular adhesion molecule-1) and LFA-1 (lymphocyte
function-associated antigen-1) [53, 54] enhance the overall efficiency of virus entry.
Primary HIV-2 isolates generally infect CD4− co-receptor+ cells more efficiently than HIV-1 [55,
56]. In these infections, CXCR4 plays a crucial role [56].
In glioma cell line (D-54 cells) binding of recombinant gp120 to the GalC or sGalC and a 180
kDa receptor activates signal transduction by a tyrosine-kinase which phosphorylates 130- and
115-kDa proteins [57]. It shows that not only main receptors but also the alternative receptors
involved in signal transduction and host protein modifications in HIV-1 infections but the
differences were observed in efficiency of infection and disease progression. It also conveys
that HIV envelope glycoprotein can specifically bind to the different host cell surface receptors
which can function as receptor or co-receptor and this feature provides flexibility to virus to
infect wide variety of host cell types [56].
3.1. Fusion and internalization of viral particles
The HIV envelope glycoprotein is responsible not only for the virus attachment to the cell
surface but also mediates viral entry. The two parts of the envelope; gp41 and gp120 trimer
forms a functional unit, which under goes a series of structural changes (Fig. 2) upon binding
to the CD4 and an appropriate chemokine receptors. These interactions promote conforma‐
tional changes in gp120 and gp41, respectively. These changes exposes the fusion domain of
the gp41 and allows to undergo fusion [58-60]. In the viral infection co-receptor has a crucial
role in fusion. Fusion of viral particles in the absence of CD4 was observed but in the absence
of co-receptor was not yet identified. Following attachment to the receptors, some virus
particles enters into endosomes (Fig. 3) later the low pH of the endosomes promotes fusion
[61]. However, HIV uses a co-receptor dependent and independent of pH [62].
Figure 2. Schematic representation of structural changes in gp120 and gp41. Different conformational changes in
gp120 and gp41 up on binding to the host cell surface receptors were represented schematically. From left, structures
of the virion envelope gp120 before binding. Once gp120 bound to CD4 of host cell, structural change in the gp120
region in the pink dotted circle. The extreme right represents the changes in the gp120 and especially gp41 once recep‐
tor and co-receptor of the host cell interacts with gp120 of virus labeled in pink dotted circle.
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Figure 3. HIV-1 entry strategies. Two well reported strategies of HIV-1 entry into host cell. The direct membrane fu‐
sion upon binding to the CD4 and co-receptors like CCR5/CXCR4 and endocytosis mediated entry upon receptor and
co-receptors binding were represented schematically.
CD4 is the primary receptor for HIVs, but virus penetration requires further interactions with
chemokine receptor CCR5 or CXCR4. Earlier studies proposed that binding to co-receptor
initiate fusion directly at the plasma membrane. The ability of formation of syncytia, and
evidences of putative fusion events at the cell surface have supported the direct fusion at the
plasma membrane [63]. However, recent evidence with endocytosis inhibitors and single-
particle tracking revealed fusion and infection occur after endocytic uptake [64, 65]. Moreover,
in macrophages HIV infection occurs through macropinocytosis [66, 67]. Based on the receptor
density and mobility, the mode of viral entry to the host cell whether fusion on cell surface or
after endocytosis will be determined [68].
3.2. Receptor-mediated endocytosis
Adhesion to the receptor initiates later events which enable viruses to enter the cytosol. The
cortex is the potential barrier to prevent entry of large molecules [69]. Receptor-mediated
signaling induced by envelope of the viruses allow viruses that undergo penetration at the cell
surface and transit the cortex [70-72]. In HIV, Gαi (a heterotrimeric G protein subunit that
inhibits the production of cAMP from ATP [73]) and CXCR4 on resting CD4+ve T cells activate
cofilin which induces reorganization of the cortex that facilitates infection [71]. This evolve‐
ment of use of different mechanisms of viral invasion into host cell may have distinct advan‐
tages for virus, which provides broader range of cell types to infect or different ways to infect
a same cell type [68] to bypass the host restriction mechanisms.
Immediately after its release into the cytoplasm, the viral core undergoes a partial and
progressive disassembly, known as uncoating, that leads to the generation of sub viral particles
called reverse-transcription complexes (RTCs) and pre-integration complexes (PICs). In HIV-1
the uncoating of capsid is coupled to the initiation of reverse transcription [74].
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4. Reverse transcription of viral RNA
4.1. Uncoating of capsid
The events in retrovirus infection that occur between entry into the host cell and reverse
transcription are less understood. Uncoating is the process of disintegration of the capsid and
release of its components into the cytoplasm of the host cell. The uncoating of the HIV-1 capsid
is thought to precede reverse transcription, whereas MLV capsid proteins remain associated
with the reverse transcription and pre-integration complexes [75-77]. The uncoating of capsid
is a temporarily regulated [78] and the host cell factors involved are poorly understood. There
are few known host proteins function as restriction factors and block the HIV-1 infection. One
of them is TRIM5α, which prevents retrovirus infection by disrupting an early, post entry
events by associating with the retroviral capsid [79, 80]. In owl monkeys, RBCC domains of
TRIM5 fused with cyclophilin A (CypA), a known capsid ligand, was identified. [81-87].
Mechanism of Cyp A in capsid uncoating or some other step in the post-entry phases of the
HIV-1 life cycle not clearly understood [88]. TRIM5 has multiple roles in early infection. It can
interfere with the uncoating process, intercept reverse transcription and viral genome trans‐
port to the nucleus by binding to the capsid proteins [89].
In vitro, uncoating of HIV-1 capsid required activated CD4+ lymphocytes. Two distinct cellular
factors with molecular mass of approximately 60 and 160 kDa were found to be involved in
capsid uncoating [90]. In contrary, cyclophilins mediated activation of T-cells by regulating
the activity of calcineurin, a phosphatase necessary for T-cell activation was reported. [91]
4.2. Reverse transcription (Reverse transcriptase and cellular factors: regulators of HIV-1
reverse transcription)
Reverse transcription takes place in a complex organization called reverse transcription
complex (RTC), is a nucleoprotein complex comprising viral RNA, a tRNA primer and newly
synthesized DNA, along with these nucleic acids, viral factors and host factors present. Reverse
transcription complex (RTC) is a composite organization of nucleoprotein complex comprising
of viral RNA, tRNA primer and synthesized DNA where the reverse transcription takes place.
RTC comprises of several other nucleic acids, host and viral factors.
The first host factors in association with reverse transcription which are packaged in virus
particles is cellular tRNALys3, which is bound to the aminoacyl-tRNALys3, synthetase (LysRS)
[92]. tRNALys3 works as a primer by binding to the primer binding site (PBS) [93] of the HIV-1
genomic mRNA and is the first step in reverse transcription. Initiation of reverse transcription
refers to the addition of the first five deoxynucleotides to the tRNALys3 primer [94]. Several
cellular factors which bound to Integrase (IN) and effects reverse transcription were identified
[95] but their direct role in reverse transcription not yet illustrated. Some of the known cellular
proteins are integrase interactor 1 (INI1, hSNF5) [96, 97], sin3A-associated protein (SAP18),
histone deactylase 1 (HDAC1) [98] and survival motor neuron (SMN)-interacting protein 2
(Gemin2) [99].
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INI1 is a component of the SWI/SNF chromatin remodeling complex of host cell [100] and is
associated with virus. INI 1 Packaging into virus is specific for HIV-1 and is regulated by a
direct interaction with the IN domain of the HIV-1 Gag-Pol protein [101]. INI1 associates with
viral RTC/PIC [102] and stimulates IN [96] activity moreover involved in the regulation of
reverse transcription.
Like INI1 of SWI/SNF complex, Sin3a-HDAC1 complex members Sin3a, Sap18, Sap30, and
HDAC1 were found in virion [98]. HDAC1 is required for the initiation of reverse transcription
and involved in a step between uncoating and reverse transcription which results in defective
viral cDNA synthesis [98]. Another IN binding protein is Gemin2 is shown to be required for
an early reverse transcription product (negative strand strong stop) or integration of viral
DNA, suggesting that Gemin2 association with either the reverse transcription or pre-
integration complexes [99]. It can recruit other cellular factors like DHX9 (RNA helicase A)
[103], which intern associated with the SMN complex [104]. But the precise mechanism of how
Gemin2 affects early replication remains to be determined.
Human antigen R (HuR) is a nuclear protein with nucleocytoplasmic shuttling capabilities [105].
It is a RNA binding protein with 3 RNA binding domains and exhibits high specificity and
affinity for AU-rich elements (AREs) [106, 107]. HuR is required for optimal reverse transcrip‐
tion. While the mechanism behind this activity remains unclear, it appears to be due to an
interaction with the RNase H domain of RT [108]. APOBEC3G (hA3G), is a host protein with
negative effects on reverse transcription [109-112]. Furthermore, hA3G was a member of
several ribonucleoproteins including DHX9 [103], hnRNP U [113], PABPC1 [114], YB-1 and
SNRPA [115] which can affect HIV-1 replication including reverse transcription. A direct
interaction between hA3G and HuR was reported [116]. By formation of protein complex,
hA3G and HuR could regulate the functions of RTC in the cytoplasm.
A kinase anchor protein 1 (AKAP1) which bind the regulatory subunits of cAMP-dependent
protein kinase A (PKA) and anchors them to various membranes throughout the cell [117].
Interaction between AKAP149 and HIV-1 RT was also reported [108]. Like HuR, it interacts
with the RNase H region of RT but the mechanism of RT regulation was not yet clearly
understood. DNA topoisomerases 1 (TOP1) is another host protein which interact with HIV-1
NC and participate in the initiation of the cDNA synthesis by enhancing the activity of HIV-1
RT [118, 119].
Several  studies  were  conducted  on  the  role  of  Topoisomerase  II  in  HIV-1  infection.  In
eukaryotes two isoforms of topoisomerase II (Topo II) was identified. The smaller one is
170kDa topoisomerase II alpha (Topo IIα) and the bigger one is 180 kDa topoisomerase II
beta (Topo IIβ) [120]. Recent evidence has proven their key role in viral infections [121, 122].
In response to HIV-1 infection, increased protein levels of Topo IIα and β were observed
[123,  124].  Both  of  these  isoforms  were  reported  to  undergo  phosphorylation  in  HIV-1
infection [125-127]. These isoforms are phosphorylated by serine kinase present in the purified
HIV-1  virion  and  are  associated  with  pre-integration  complexes  (PICs)  [126].  Topo  II
inhibitors abrogate HIV-1 replication cycle by interfering with the PICs formation [128]. Down
regulation if these isoforms using siRNA resulting in impaired HIV-1 replication [124,129,
130] due to the incomplete reverse transcription. Co-localization studies reveled the associa‐
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tion of these isoforms with HIV-1 reverse transcriptase [124]. Similar to this, another host
protein HMGI(Y) reported to be with involvement in covalent strand transfer in HIV-1 reverse
transcription. [131].
APOBEC3G (apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G, (A3G))
belong to a group of interferon-stimulated gene [132] and is an editing enzyme for nucleic
acids. It blocks virus replication by deamination of viral minus-strand DNA, resulting in G-
to-A hyper mutation. In addition to the deaminase activity, A3G has also been shown to
directly inhibit HIV-1 reverse transcription by a non-editing mechanism [133, 134]. A3G may
also reduce viral DNA synthesis and can inducing viral DNA degradation by interacting
physically with HIV-1 reverse transcriptase [135]. Its action was blocked by the viral protein
Vif and another host protein apoptosis signal-regulating kinase 1 (ASK1) by binding to Vif
restores A3G function [136]. Cyclin-dependent kinase (CDK) 2 is a host protein which regulates
the reverse transcriptase by phosphorylating on threonine which improves the increased
efficiency and stability of reverse transcriptase and enhanced viral fitness. p21, a cell-intrinsic
CDK inhibitor, counteracts the CDK2-dependent phosphorylation and significantly reduced
the efficacy of viral reverse transcription [137].
4.3. Pre-integration complex formation
Immediately after disintegration of the capsid into the host cytosol, the viral +stand genomic
RNA converted into double stranded DNA. This newly synthesized viral genomic DNA
wrapped around the host and viral proteins in a protective manner and protected from
nuclease degradation [138]. The viral single-stranded RNA genome is converted into a linear
double-stranded DNA. The viral DNA intermediate then migrates to the cell nucleus and is
covalently integrated into a host chromosome. The integration of reverse transcribed HIV-1
cDNA into a host cell chromosome is an essential step in the viral replication cycle [108, 109].
Retroviral integration in vivo is mediated by pre-integration complexes (PICs). PICs are be
formed with viral and host cell proteins like high-mobility group protein A1 (HMGA1) and
the barrier-to-auto-integration factor (BAF) which were well studied and identified their
functions as cofactors for integration [139]. HMG I(Y) is another host protein required for the
proper function of the PICs in vitro [131]. Other proteins like XRCC6, TFRC and HSP70 were
identified as in association with viral DNA [140]. Topoisomerase IIα and β isoforms were also
identified as nucleoprotein components of PICs, which suggesting their significant role in
HIV-1 replication [128].
5. Integration of viral DNA into host genome
Integration of the viral DNA is mediated by PICs formation. These PICs are capable of
performing integration in vitro. Even though specific (HMG I(Y)) and non-specific (bovine
RNase A) could able to restore the activity, but only BAF can restore the native structure of
the HIV-1 protein–DNA intasome from salt stripped PICs [141]. HIV-1 integration in host
genome is not a random event. In majority of cases, it takes place in AT rich, euchromatin
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region. Even though PIC formation can protect the DNA and helps in the nuclear transport, it
cannot guide the integration in a proper location in the host genome. A host protein called
cellular lens epithelium-derived growth factor (LEDGF/p75) which binds both chromosomal
DNA and HIV integrase [142], directs the integration to a location where active transcription
takes place under its control [143]. The interaction between the integrase and INI1 stimulates
the DNA-joining activity of the integrase and helps to target the viral DNA towards active
genes [96, 102, 144]. Presence of a Topo II cleavage site in the HIV-1 promoter and also at 180
bp upstream of the HIV-1 integration site [145, 146] and association of these Topo II isoforms
with HIV-1 PICs [128]. Based on the available information, it can be derived that, IN alone can
carry out the integration reaction but for the selection of the proper location in the host genome
for the integration and success full HIV-1 gene transcription, Integrase required the support
of the host factors.
5.1. Transport of PICs into nucleus
Transportation of the PICs to the nucleus can be divided in two parts. One is transportation
to the nuclear periphery and second is from periphery to inside the nucleus. After completion
of the successful cell surface attachment, capsid internalization and degradation in cytoplasm
which leads to the reverse transcription of the viral genome RNA to DNA and the formation
of the pre-integration complex to protect the DNA from the host nucleases takes place. This
nucleoprotein PICs should travel from the cytosol to the nucleus to form provirus which is an
integrated viral DNA in host chromatin and can produce progeny virus [147, 148].
The PICs in the cytoplasm translocate to the perinuclear compartment by the cytoplasmic
movements by the cytoskeleton. Actin and microtubule [149] selectively plays a role in this
transport with the help of Myosin VI and Dynein [148]. The dynein complex proteins such as
dynein light chain1 (DYNLL1), Tctex1 and Dynactin have been shown to be involved in this
process. But very little is known about how HIV-1 targets cytoskeleton. Many of the viral
elements found in association with the PIC have been proposed to be important for HIV-1
nuclear import.
Studies on the HIV-1 infection in dividing and non-dividing cells provided enough evidences
to believe that PICs enter the nucleoplasm by crossing the nuclear envelope through nuclear
pore complexes (NPCs), which form stable channels through the nuclear envelope and gate-
keep the trafficking of molecules between the nucleus and cytoplasm [150]. The RTC/PIC with
the size of~100-250nm [149, 151, 152] cannot cross the nuclear pore. So, only few important
components of the PIC may enter into the nucleus [149, 152].
For nuclear transport, KPNs and NUPs functions as carrier proteins by binding to the integrase.
KPN α adaptor proteins importin α1 (Rch1) [153] and importin α3 (KPNA4) [154], to which
KPN β1 proteins bound additionally. Importin 7 [155, 156] and transportin 3 [157, 158] are
recruited by the nuclear localization signal (NLS) present on IN. In both dividing and non-
dividing cells Impα3 which interacts with IN is found to be essential nuclear import and
replication [154]. In addition to these, IN can directly interact with the KPN β1, NUP153 [159],
Pom121 [160] or hCG1 [161] who has possible interactions with IN and Vpr and can facilitate
nuclear import [162].
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6. Summary
After 33 years of the identification of HIV-1 infection, very little is known about the role of host
cellular proteins. Till now considerable work has been done in the area of host–pathogen
interactions facilitated by the viral proteins and host receptors. The role of the main receptor
like CD4 and co-receptors like CCR5, CXCR4 and their alternative receptors were well studied
with the role of their signaling in disease progression. But the intracellular events of the host–
pathogen interactions were poorly understood. Much data is available based on the global
wide analysis of genome-wide RNA interference screens, yeast two-hybrid system and co-
immunoprecipitation studies but their exact roles were not yet characterized. There are very
few host proteins like APOBEC3G, LEDGF/p75, INI1, HMG I(Y) and BAF, which were well
studied and characterized. Majority of the reported proteins were attributed with multiple
functions. It is very useful to study such proteins to develop as future candidates to HIV-1
therapy.
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